Breaking News Instant updates and real-time market news.

CURO

Curo Group

$23.09

0.09 (0.39%)

, HUYA

HUYA

$38.94

2.68 (7.39%)

08:30
06/14/18
06/14
08:30
06/14/18
08:30

Four new option listings and one option delisting on June 14th

New option listings for June 14th include CURO Group Holdings Corp (CURO), HUYA Inc (Class A ADS) (HUYA), Madrigal Pharmaceuticals (MDGL), and comScore Inc (SCOR). Option delistings effective June 14th include Ablynx NV (ADR) (ABLX).

CURO

Curo Group

$23.09

0.09 (0.39%)

HUYA

HUYA

$38.94

2.68 (7.39%)

MDGL

Madrigal Pharmaceuticals

$313.25

31.25 (11.08%)

SCOR

comScore

$24.64

-0.16 (-0.65%)

ABLX

Ablynx

$52.91

(0.00%)

CURO Curo Group
$23.09

0.09 (0.39%)

04/30/18
FBCO
04/30/18
NO CHANGE
Target $26
FBCO
Outperform
Curo Group price target raised to $26 from $21 at Credit Suisse
Credit Suisse analyst Moshe Orenbuch raised his price target for Curo Group to $26 from $21, citing a revenue beat, strong 2018 guidance, and tax reform that is likely a Q2 positive. The analyst reiterates an Outperform rating on the shares.
05/08/18
JEFF
05/08/18
NO CHANGE
Target $30
JEFF
Buy
Curo Group shares have 'meaningful upside,' says Jefferies
After hosting investor meetings with management, Jefferies analyst John Hecht remains favorable on Curo Group as one of his top picks in the alternative consumer finance space. With ongoing execution, Curo's discount to peers should disappear, Hecht tells investors in a research note. The analyst sees "meaningful upside" from current stock price levels and keeps a Buy rating on the shares with a $30 price target.
01/11/18
JANY
01/11/18
INITIATION
Target $19
JANY
Buy
Curo Group initiated with a Buy at Janney Capital
Janney Capital analyst John Rowan started Curo Group with a Buy rating $19 fair value estimate.
04/17/18
SPHN
04/17/18
NO CHANGE
Target $23
SPHN
Overweight
Curo Group named a new best idea at Stephens
Stephens analyst Vincent Caintic named Curo Group (CURO) his new best idea, replacing Alliance Data (ADS), as he believes Curo's online plus branch-based distribution model can power year-over-year EPS growth of 40% in 2019. The analyst noted that he still likes Alliance Data, but he thinks the shares will be muted until credit improves in the second half of the year. Caintic has an Overweight rating and $23 price target on Curo Group.
HUYA HUYA
$38.94

2.68 (7.39%)

06/13/18
NEED
06/13/18
INITIATION
Target $41
NEED
Buy
HUYA initiated with a Buy at Needham
Needham analyst Jinjin Qian initiated HUYA (HUYA) with a Buy rating and a price target of $41, citing the company's platform as a leader in live game streaming in China with 92.9M monthly active users. The analyst also points to "strong secular trends" in e-sports and live streaming, along with its close ties with YY (YY) and Tencent (TCEHY), supporting the company's position. Jinjin Qian calls HUYA a "solid" investment based on its "strong user metrics and scalable business model".
06/07/18
UBSW
06/07/18
INITIATION
UBSW
Neutral
HUYA initiated with a Neutral at UBS
MDGL Madrigal Pharmaceuticals
$313.25

31.25 (11.08%)

06/12/18
MAXM
06/12/18
NO CHANGE
Target $30
MAXM
Buy
Galmed price target raised to $30 from $14 at Maxim
Maxim analyst Jason McCarthy raised his outyear estimates for Aramchol and reduced his risk adjustment to 15% from 30% following the announcement of Galmed's (GLMD) Phase 2b data for Aramchol in NASH. Given the changes, he raised his price target on Galmed shares to $30 from $14, which he notes implies a market capitalization of $450M. That valuation may be viewed as "conservative" given the rise in valuations of others in the NASH space, including Madrigal (MDGL), which McCarthy said completed a Phase 2 study that was "smaller and shorter" than Galmed. He maintains a Buy rating on Galmed shares, which are up $13, or 185% to about $20 per share in afternoon trading.
06/07/18
EVER
06/07/18
NO CHANGE
Target $300
EVER
Outperform
Evercore ISI 'comfortable' with $300 price target on Madrigal after secondary
Evercore ISI analyst Josh Schimmer said he remains "comfortable" with his $300 price target on Madrigal Pharmaceuticals despite the stock trading off following the company's secondary offering of stock. After fielding calls from investors, Schimmer thinks a lack of catalysts "is probably the number one concern," as the company hopes to be able to start a Phase 3 NASH trial by year-end, which "probably means a 2-3 year void of news flow." Schimmer also listed long-term safety and efficacy and competitive dynamics as concerns voiced by investors he spoke with. He maintains an Outperform rating on Madrigal, which dropped over 10% in today's trading to about $281 per share.
06/05/18
MAXM
06/05/18
NO CHANGE
Target $14
MAXM
Buy
Chances of beta agonist success favors Viking Therapeutics, says Maxim
After Viking Therapeutics (VKTX) announced that enrollment has been completed in the company's ongoing Phase 2 clinical trial of VK2809 in patients with primary hypercholesterolemia and non-alcoholic fatty liver disease, Maxim analyst Jason McCarthy said that given Viking's prior data and the data for Madrigal's (MDGL) MGL-3196, which is in the same class of Thyroid Hormone Receptor beta agonists, that he believes the probability of success favors Viking. He maintains a Buy rating and $14 price target on Viking shares.
06/14/18
HCWC
06/14/18
NO CHANGE
Target $15
HCWC
Buy
H.C. Wainwright says don't forget about Viking with Madrigal in play
After Bloomberg reported that Madrigal Pharmaceuticals (MDGL) is exploring a sale after receiving takeover interest, H.C. Wainwright analyst Joseph Pantginis tells investors to not forget about Viking Therapeutics (VKTX). The latter's potential treatment for non-alcoholic steatohepatitis, VK2809, could be even better than Madrigal's, Pantginis contends. The analyst believes that with Madrigal in play, it continues to bring "deserved focus to VK2809, which should garner significant business development interest as well." The analyst thinks VK2809 is "just starting to realize its underlying value from an investment standpoint." Citing the market potential for VK2809 and VK5211, the analyst highlights the value disconnect when comparing Madrigal's market capitalization of $4.8B with Viking's at $652M. Pantginis keeps a Buy rating on Viking Therapeutics with a $15 price target.
SCOR comScore
$24.64

-0.16 (-0.65%)

09/06/17
PIVT
09/06/17
NO CHANGE
Target $140
PIVT
Sell
Pivotal says Facebook ad reach claims look inflated
Pivotal Research analyst Brian Wieser noted that Australian trade publication AdNews found that Facebook (FB) claims to reach more 16-39 year-olds in the country than exist according to the country's census. His analysis of Facebook Ads Manager data compared to the U.S. consensus reveals a similar outcome. His talks with ad agency executives on this topic indicate that the gap between Facebook and census figures is not widely known, Wieser tells investors. The analyst, who keeps a Sell rating and $140 price target on Facebook, believes the primary winner of the social media giant's video expansion will be third party measurement firms, such as Nielsen (NLSN) and comScore (SCOR), he added.
09/12/17
NEED
09/12/17
NO CHANGE
NEED
comScore acquisition has become more likely, says Needham
After comScore announced that its CFO and seven members of its board were leaving and that two of its directors would work with Starboard to conduct a strategic review, Needham analyst Laura Martin thinks that a sale of the company has become more likely. However, she believes that it is "too early for fundamental investors to get involved" with the company and continues to refrain from publishing a rating on the stock.
06/12/18
06/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. InterDigital (IDCC) initiated with a Buy at Roth Capital. 2. Weight Watchers (WTW) initiated with an Overweight at JPMorgan and a Buy at DA Davidson. 3. Franklin Electric (FELE) initiated with a Neutral at DA Davidson. 4. ArQule (ARQL) initiated with an Outperform at Oppenheimer. 5. comScore (SCOR) initiated with a Buy at Loop Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/11/18
LOOP
06/11/18
INITIATION
Target $32
LOOP
Buy
comScore initiated with a Buy at Loop Capital
Loop Capital analyst Alan Gould initiated comScore with a Buy rating and a price target of $32, saying the company's recent naming of a new CEO and re-listing on the Nasdaq marks a "new beginning". Gould notes that after several management changes over the past few years, comScore has started to show some revenue growth in the most recent quarter. The analyst adds that it will take some time for the new CEO to disclose and execute on his vision, but believes that there is "substantial upside" to comScore's current value.
ABLX Ablynx
$52.91

(0.00%)

01/29/18
BARD
01/29/18
DOWNGRADE
Target $56
BARD
Neutral
Ablynx downgraded to Neutral from Outperform at Baird
Sanofi (SNY) and Ablynx (ABLX) entered into a definitive agreement under which Sanofi will offer to acquire Ablynx.
01/08/18
DBAB
01/08/18
NO CHANGE
DBAB
Buy
Novo offer for Ablynx makes strategic sense, says Deutsche Bank
Deutsche Bank analyst Tim Race views Novo Nordisk's (NVO) acquisition offer for Ablynx (ABLX) as sensible, fitting with the stated company strategy and at a reasonable price. Depending on how discussions develop, the analyst would expect Novo to potentially raise its offer. Ablynx's caplacizumab could leverage Novo's readymade global haematology sales force with minimal additional cost, Race tells investors in a research note. The analyst keeps a Buy rating on Novo Nordisk.
11/20/17
11/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Innoviva (INVA) initiated with a Hold at Deutsche Bank. 2. National Vision (EYE) was initiated with an Overweight at Morgan Stanley, an Outperform at Wells Fargo, a Buy at Jefferies and Citi, as well as a Neutral at Goldman Sachs, UBS, and BofA/Merrill. 3. Ablynx (ABLX) was initiated with an Overweight at JPMorgan, an Outperform at Baird, and a Buy at Ladenburg. 4. Blue Apron (APRN) initiated with a Sector Weight at KeyBanc. 5. BP Midstream (BPMP) was initiated with an Overweight at JPMorgan, a Buy at UBS and Citi, an Equal Weight at Morgan Stanley and Barclays, as well as a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/09/18
BARD
01/09/18
NO CHANGE
Target $33
BARD
Outperform
Ablynx bid a floor for shares, other bids could follow, says Baird
Baird analyst Brian Skorney noted Novo Nordisk (NVO) went public with its $3.1B bid for Ablynx (ABLX). He believes the shares will trade above that level and that a new bid will emerge, although there are no other bidders yet. Skorney reiterated his Outperform rating and $33 price target on Ablynx shares.

TODAY'S FREE FLY STORIES

MUX

McEwen Mining

$2.18

0.035 (1.64%)

12:13
06/19/18
06/19
12:13
06/19/18
12:13
Hot Stocks
McEwen Mining COO Xavier Ochoa to resign effective July 13 »

On June 13, Xavier Ochoa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GFN

General Finance Corp

$11.85

-0.05 (-0.42%)

12:10
06/19/18
06/19
12:10
06/19/18
12:10
Hot Stocks
Havner Family Trust buys 10K shares of General Finance »

The Havner Family Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVS

Las Vegas Sands

$79.70

-0.83 (-1.03%)

12:10
06/19/18
06/19
12:10
06/19/18
12:10
Options
Put buyer opens downside hedge in Las Vegas Sands after record high »

Put buyer opens downside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

PTC

PTC

$97.72

-0.08 (-0.08%)

12:07
06/19/18
06/19
12:07
06/19/18
12:07
Hot Stocks
PTC, Elysium announce new design, validation app for ThingWorx Navigate »

PTC announced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMI

Kinder Morgan

$17.21

0.04 (0.23%)

12:05
06/19/18
06/19
12:05
06/19/18
12:05
Options
Kinder Morgan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$60.53

0.16 (0.27%)

, S

Sprint

$5.56

0.01 (0.18%)

12:03
06/19/18
06/19
12:03
06/19/18
12:03
Hot Stocks
T-Mobile, Sprint officially file merger plans with FCC »

T-Mobile US (TMUS) and…

TMUS

T-Mobile

$60.53

0.16 (0.27%)

S

Sprint

$5.56

0.01 (0.18%)

DTEGY

Deutsche Telekom

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$195.71

-2.59 (-1.31%)

12:01
06/19/18
06/19
12:01
06/19/18
12:01
Periodicals
Facebook misses 'deadline' to answer Senator's questions, Bloomberg says »

Facebook has missed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

TCI

Transcontinental Realty Inc

$36.00

2.54 (7.59%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Hot Stocks
Transcontinental Realty, Adobe Properties say advisor may make stock purchases »

Transcontinental Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMAR

Smartsheet

$29.00

-3.07 (-9.57%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Hot Stocks
Smartsheet falls -9.9% »

Smartsheet is down -9.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYX

Systemax

$35.40

-4 (-10.15%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Hot Stocks
Systemax falls -10.5% »

Systemax is down -10.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$125.30

-2.2 (-1.73%)

, EADSY

Airbus

$0.00

(0.00%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Periodicals
Pratt & Whitney close to fix for part that delayed Airbus jets, Bloomberg says »

Pratt & Whitney,…

UTX

United Technologies

$125.30

-2.2 (-1.73%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$27.24

-4.92 (-15.30%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Hot Stocks
PagSeguro Digital falls -15.1% »

PagSeguro Digital is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

EBR

Centrais Electricas

$3.71

0.21 (6.00%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Hot Stocks
Centrais Electricas rises 6.3% »

Centrais Electricas is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$10.44

0.795 (8.24%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Hot Stocks
ProShares Trust Ultra VIX Short Term Futures ETF rises 8.0% »

ProShares Trust Ultra VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COTV

Cotiviti Holdings

$44.02

4.13 (10.35%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Hot Stocks
Cotiviti Holdings rises 10.4% »

Cotiviti Holdings is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARRY

Array BioPharma

$17.90

0.4 (2.29%)

11:57
06/19/18
06/19
11:57
06/19/18
11:57
Conference/Events
Array BioPharma to hold a conference call »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 30

    Jun

  • 30

    Jun

VZ

Verizon

$48.69

1.23 (2.59%)

11:57
06/19/18
06/19
11:57
06/19/18
11:57
Periodicals
Verizon to cease sharing phone-location data of customers, Reuters reports »

Verizon will stop sharing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

USCR

U.S. Concrete

$63.30

-1.1 (-1.71%)

11:53
06/19/18
06/19
11:53
06/19/18
11:53
Hot Stocks
U.S. Concrete rating downgraded to B2 from B1 by Moody's »

Moody's Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

JD

JD.com

$41.57

-2.18 (-4.98%)

11:50
06/19/18
06/19
11:50
06/19/18
11:50
Options
Continued interest in JD Jun 22nd 45 calls even as shares slide »

Continued interest in JD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:50
06/19/18
06/19
11:50
06/19/18
11:50
General news
Treasury's bill auctions were about average »

Treasury's bill…

KO

Coca-Cola

$43.57

0.01 (0.02%)

11:47
06/19/18
06/19
11:47
06/19/18
11:47
Hot Stocks
Arby's announces conversion to Coca-Cola beverages »

Arby's announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

21st Century Fox

$44.44

0.09 (0.20%)

, FOXA

21st Century Fox

$44.70

0.145 (0.33%)

11:43
06/19/18
06/19
11:43
06/19/18
11:43
Hot Stocks
21st Century Fox says 'looks forward' to final decision clearing transaction »

21st Century Fox (FOXA)…

FOX

21st Century Fox

$44.44

0.09 (0.20%)

FOXA

21st Century Fox

$44.70

0.145 (0.33%)

SKYAY

Sky

$0.00

(0.00%)

DIS

Disney

$106.00

-1.05 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEA

China Eastern Airlines

$42.19

-0.49 (-1.15%)

, EADSY

Airbus

$0.00

(0.00%)

11:41
06/19/18
06/19
11:41
06/19/18
11:41
Periodicals
China Eastern calls for bids to supply 150 jetliners, Reuters says »

China Eastern (CEA) is…

CEA

China Eastern Airlines

$42.19

-0.49 (-1.15%)

EADSY

Airbus

$0.00

(0.00%)

BA

Boeing

$343.13

-11.66 (-3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$161.63

56.15 (53.23%)

11:40
06/19/18
06/19
11:40
06/19/18
11:40
Options
Sarepta Therapeutics call buyer hits a home run »

Sarepta Therapeutics call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

11:40
06/19/18
06/19
11:40
06/19/18
11:40
General news
Atlanta Fed's Q2 GDPNow estimate was nudged down to 4.7% »

Atlanta Fed's Q2…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.